The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Qualcomm earnings beat Wall Street expectations, as revenue jumped. But IP licensing revenue missed estimates and stock fell 4.8%. Skyworks Solutions plunged after it said it expected its share of the ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.